Finished Dosage Form (FDF) import of Imipenem And Cilastatin Sodium obtained from Indian Custom Trade Statistics

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as:
Molecular Formula
C28H43N6NaO9S
Molecular Weight
662.7  g/mol
InChI Key
ZUYXKOGCKYEFON-UHFFFAOYSA-M

Imipenem And Cilastatin Sodium
1 2D Structure

Imipenem And Cilastatin Sodium

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
sodium;7-(2-amino-2-carboxyethyl)sulfanyl-2-[(2,2-dimethylcyclopropanecarbonyl)amino]hept-2-enoate;3-[2-(aminomethylideneamino)ethylamino]-6-(1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
2.1.2 InChI
InChI=1S/C16H26N2O5S.C12H18N4O4.Na/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21;1-6(17)9-8-4-7(15-3-2-14-5-13)10(12(19)20)16(8)11(9)18;/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23);5-6,8-9,15,17H,2-4H2,1H3,(H2,13,14)(H,19,20);/q;;+1/p-1
2.1.3 InChI Key
ZUYXKOGCKYEFON-UHFFFAOYSA-M
2.1.4 Canonical SMILES
CC(C1C2CC(=C(N2C1=O)C(=O)O)NCCN=CN)O.CC1(CC1C(=O)NC(=CCCCCSCC(C(=O)O)N)C(=O)[O-])C.[Na+]
2.2 Create Date
2011-10-30
3 Chemical and Physical Properties
Molecular Weight 662.7 g/mol
Molecular Formula C28H43N6NaO9S
Hydrogen Bond Donor Count7
Hydrogen Bond Acceptor Count13
Rotatable Bond Count17
Exact Mass662.27099243 g/mol
Monoisotopic Mass662.27099243 g/mol
Topological Polar Surface Area286 Ų
Heavy Atom Count45
Formal Charge0
Complexity1010
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count5
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count1
Covalently Bonded Unit Count3

API SUPPLIERS

read-more
read-more

01

Savior Lifetec Corporation

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Luxepack
Not Confirmed
arrow

Savior Lifetec Corporation

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Luxepack
Not Confirmed
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

02

Hospira, Inc.

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Luxepack
Not Confirmed
arrow

Hospira, Inc.

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Luxepack
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

03

Jeil Pharmaceutical Co., Ltd

South Korea

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Luxepack
Not Confirmed
arrow

04

High Science Co., Ltd

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Luxepack
Not Confirmed
arrow

05

JW Pharmaceutical Corporation

South Korea

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Luxepack
Not Confirmed
arrow

JW Pharmaceutical Corporation

South Korea

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Luxepack
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

Luxepack
Not Confirmed

02

Savior Lifetec Corp

Taiwan

USDMF

arrow
Discovery on Target
Not Confirmed
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Luxepack
Not Confirmed
arrow
arrow
Luxepack
Not Confirmed

Imipenem And Cilastatin Sodium

About the Company : We focus on development of carbapenem APIs. In hospital, these drugs are used for complicated infections. As a last-line antibiotic, the consumption is increased every year attribu...

We focus on development of carbapenem APIs. In hospital, these drugs are used for complicated infections. As a last-line antibiotic, the consumption is increased every year attributing to bacteria resistance. Carbapenem APIs are difficult to produce. High Science develops key synthesis technique and sterile processing, and we have excellent management team, Quality system design, advanced process control system, and individual factory. High Science Taiwan focuses on R&D, and cooperates with academic units. We always provide high quality APIs.
blank

02

Luxepack
Not Confirmed
arrow
arrow
Luxepack
Not Confirmed

Sterile Imipenem/ Cilastatin Sodium

About the Company : Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGM...

Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to general, special, and aseptic pharmaceuticals.On the other hands, JEIL is manufacturing FDF Products sold to Japan and other countries.With marketing strategy of 'First generic' and Innovative drug, JEIL have been extended the market in world-wide.
blank

03

Luxepack
Not Confirmed
arrow
arrow
Luxepack
Not Confirmed

Imipenem And Cilastatin Sodium

About the Company : The company was formerly known as "Choongwae Pharma Corporation" and changed its name to JW Pharmaceutical on April 21, 2011. JW Pharmaceutical was founded in 1945 and is based in ...

The company was formerly known as "Choongwae Pharma Corporation" and changed its name to JW Pharmaceutical on April 21, 2011. JW Pharmaceutical was founded in 1945 and is based in Seoul, South Korea. JW Pharmaceutical CORPORATION, who has been leading hospital market with its medical products, is strengthening its global competitiveness by getting the outstanding pipeline for original medicine and medical supplies and putting its passion to develop innovative new medicine through its global R&D network.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty